Novartis Docket No.: PAT051105-US-CNT01 Mofo Docket No.: 223002099101

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Vincenzo SCARLATO et al.

Patent No.: 7,714,121

Issued: May 11, 2010

For: MENINGOCOCCAL ANTIGENS

REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 CFR 1.322

Attention: Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Certain typographical errors relating to ORF40-1.pep have been raised to the attention of the Patentee which should be corrected

At Column 47, Line 34, delete "251 SADTKTTTVN VESKDNGKKT EVKIGAXTSV IKEKDGKLVT GKDKGENGSS" and replace with --251 SADTKTTTVN VESKDNGKKT EVKIGAKTSV IKEKDGKLVT GKDKGENGSS --

At Column 47, Line 36, delete "351 ASGKGTTATV SKDDQGbUTV MYDVNVGDAL NVNQLQNSGW NLDSKAVAGS" and replace with --351 ASGKGTTATV SKDDQGNITV MYDVNVGDAL NVNOLQNSGW NLDSKAVAGS --

These errors were not due to the applicant; accordingly no fee is required. Page 66 of the specification as filed show the correct text of the patent application. In particular, the third block of amino acid sequence on line 14 of page 66 of the patent application clearly reads

Patent No.: 7.714.121

"EVKIGAKTSV" (emphasis added). By contrast, the corresponding block of amino acid sequence on Col. 47, line 34, of the issued patent reads "EVKIGAXTSV" (emphasis added). Similarly, the second block of amino acid sequence on line 16 of page 66 of the patent application clearly reads "SKDDQGNITV" (emphasis added). By contrast, the corresponding block of amino acid sequence on Col. 47, line 34, of the issued patent reads "SKDDQGNUTV" (emphasis added). In addition, the fourth block of amino acid sequence on line 14 of page 66 of the patent application clearly shows four of the ten amino acids are italicized "IKEKDGKLVT". By contrast, the corresponding block of amino acid sequence on Col. 47, line 34, of the issued patent shows no italics "IKEKDGKLVT". These errors appear to have been introduced by the USPTO through a scanning error.

Upon reviewing the above-identified patent, the Patentee has noted certain additional typographical errors also relating to ORF40-1.pep which should be corrected.

At Column 47, Line 29, delete "1 MNKIYRIIWN SALNAWVVVS ELTRNHTKRA SATVKTAVLA TLLFATVQAS" and replace with --1 MNKIYRIIWN SALNAWVVVS ELTRNHTKRA SATVKTAVLA TLLFATVQAS --

At Column 53, Lines 32-34, delete "

At Column 53, Line 37, delete "orf40-1.pep

KDKGENGSSTDEGEELVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTN VTFA" and replace with -- orf40-1.pep

 ${\tt KDKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTN} \\ {\tt VTFA} --$

3 Novartis Docket No.: PAT051105-US-CNT01 Mofo Docket No.: 223002099101

At Column 53, Line 39, delete "orf40a

Patent No.: 7.714.121

KGKGENGSSTDEGEELVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTN VTFA" and replace with -- orf40a

 ${\tt KGKGENGSSTDEGEGLVTAKEVIDAVNKAGWRMKTTTANGQTGQADKFETVTSGTN} \\ {\tt VTFA} --$

These errors were also not due to the applicant; accordingly no fee is required. Page 68 of the specification as filed show the correct text of the patent application. In particular, the fifth block of amino acid sequence on line 9 of page 66 of the patent application clearly shows three of the ten amino acids are italicized "TLLFATVOAS". By contrast, the corresponding block of amino acid sequence on Col. 47, line 29, of the issued patent shows no italics "TLLFATVOAS". In addition, the amino acid sequence on line 7 of page 68 of the patent application clearly reads "...DTXTT..." (emphasis added). By contrast, the corresponding amino acid sequence on Col. 53. line 24, of the issued patent reads "...DTKTT..." (emphasis added). Furthermore, line 6 of page 68 immediately above the "X" shows an open space "" while Col. 53, line 23 immediately above the incorrect "K" incorrectly shows a "l". In addition, the amino acid sequences on lines 5 and 7 of page 68 of the patent application clearly read "...KDGKLVTG..." (emphasis added). By contrast, the corresponding amino acid sequence on Col. 53, lines 22 and 24, of the issued patent reads "...KDGLVTG...". Finally, the amino acid sequences on lines 11 and 13 of page 68 of the patent application clearly read "...GEGLV..." (emphasis added). By contrast, the corresponding amino acid sequences on Col. 53, lines 27 and 29, of the issued patent reads "...GEELV..." (emphasis added). These errors again appear to have been introduced by the USPTO through a scanning error.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment.

Patentee respectfully solicits the granting of the requested Certificate of Correction.

Patentee further notes that further typographical errors have been noted, but such errors have not been raised in interference 105,791, so Patentee will attend to correction of these further typographical errors after the conclusion of interference 105,791.

Patent No.: 7,714,121 4 Novartis Docket No.: PAT051105-US-CNT01 Mofo Docket No.: 223002099101

In the event the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No.: 03-1952** referencing **Docket No.**223002099101. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 18, 2011 Respectfully submitted,

By /Otis Littlefield/
Otis B. Littlefield
Registration No.: 48,751

MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105-2482 Telephone: 415.268.6846

Fax: 415.268.7522